Amino-bisphosphonates
Amino-bisphosphonates has been studied in 1 paper since 2021: 1 observational study in people. The newest paper, Aug 19, 2021: “The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes”.
1 paper studies it2 findingsUpdated
See all 1 papers on amino-bisphosphonates
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“the incidence of COVID-19 hospitalization, intensive care unit (ICU) utilization, and COVID-19 potentially related mortality were similar in N-BPs-treated and nontreated subjects.”
None of its findings points the other way.
- 1 lab in 1 country
- Humans1
What did studies of amino-bisphosphonates find?
2Studies of amino-bisphosphonates measured 2 outcomes: COVID-19 potentially related mortality and COVID-19 hospitalization.
COVID-19 potentially related mortality
no changein humans1
1 study
COVID-19 potentially related mortality
no changein humans1
Amino-bisphosphonates were not clearly linked with COVID-19 potentially related mortality in humans (Compared with nonusers).
HumansCompared with nonusers
COVID-19 hospitalization
no changein humans1
1 study
COVID-19 hospitalization
no changein humans1
Amino-bisphosphonates were not clearly linked with COVID-19 hospitalization in humans (Compared with nonusers) (Incidence 12.32 (95% CI 9.61–15.04) versus 11.55 (95% CI 8.91–14.20) in users and nonusers).
HumansCompared with nonusers